FDA APPROVALS

Boston Scientific Corp. received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
While the stenting of coronary lesions continues to show a substantial improvement in quality of life for patients with coronary artery disease, ISR still encompasses 10% of percutaneous coronary interventions in the U.S. Serving as an alternative to traditional therapies, additional layers of stenting or radiation, the AGENT DCB is a paclitaxel-coated balloon catheter that transfers a therapeutic dose of drug to the vessel wall to help prevent ISR reoccurrence.
Following Breakthrough Device Designation granted for the technology by the FDA in 2021, the approval was supported by positive results from the multicenter, prospective, randomized controlled AGENT IDE trial, which enrolled 600 patients at 40 U.S. sites. In the prespecified interim analysis of the first 480 patients enrolled, the study met the primary endpoint of target lesion failure (TLF) at 12 months with the AGENT DCB demonstrating statistical superiority to uncoated balloon angioplasty (17.9% vs. 28.7%; P=0.006). Findings also included zero definite/probable cases of clotting within the stent (0.0% vs. 3.9%, P=0.001), a 49% risk reduction in heart attack at the target vessel (6.4% vs. 12.3%, P=0.03), and low adverse event rates at 12 months.
https://www.bostonscientific.com
The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements enhancing harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.
https://www.getinge.com
WANT MORE?
Enter your email to receive our newsletters.

Explore the May 2024 Issue
Check out more from this issue and find your next story to read.
Latest from Today's Medical Developments
- Pioneering battery-free cardiac implants
- KBC Tools & Machinery marks its 60th anniversary, Founder’s Day
- Address the challenges of machining high-temperature aerospace components
- Elevate your manufacturing operations with April’s Manufacturing Lunch + Learn
- AdvaMed statement on tariff announcement
- Collets – Not all are created equal
- ENGEL expands production capacities in the Americas; new plant opened in Mexico
- MFI brings fast, high-polishing additive parts finishing to Rapid + TCT 2025